Active Biotech has announced that its partner Teva Pharmaceutical Industries Ltd. will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease.
Teva started a global research collaboration in the summer of 2013 to develop laquinimod as a treatment for Huntington’s disease. Earlier this year, laquinimod was rejected twice by the CHMP that did not recommend a marketing approval within the European Union for the substance.
Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed primarily for the treatment of relapsing-remitting MS (RRMS) and progressive forms of MS. In extensive non-clinical and clinical studies, laquinimod has demonstrated anti-inflammatory and neuroprotective properties and effects that have been shown to provide clinically meaningful results, states Active Biotech.
